Peptides Under the Microscope: Regulation, Enforcement, and Market Implications

Rapid growth in the peptide market has drawn increasing attention from regulators, leaving providers, operators, and investors navigating a complex and evolving landscape. This webinar examined where peptide regulation and enforcement are heading and what it means for clinical practice and investment in this space.

Key takeaways included:

1. Peptide regulation is growing, but still highly unsettled. FDA does not maintain a standalone regulatory category for peptides, and peptides may be treated differently depending on their characteristics and intended use. Companies cannot assume all peptides fit one regulatory pathway – each product needs its own regulatory analysis. Stakeholders expect FDA’s July 2025 Pharmacy Compounding Advisory Committee meeting will provide further insight into federal peptide regulation.
2. The current peptide boom is linked to the GLP-1 compounding crackdown. As GLP-1 shortages ended and enforcement increased, many compounders shifted attention to other peptides, creating growth opportunities alongside significant uncertainty under the 503A/503B framework and FDA’s bulk-drug-list rules.
3. Advertising and marketing are a major enforcement risk area. Claims suggesting FDA approval, equivalence to approved drugs, or clinically proven benefits without adequate support, as well as white-label branding that obscures the original compounder, may draw scrutiny not only from FDA but also from the FTC, NAD, state regulators, and private litigants.
4. State law and clinical practice risks are important to evaluate. Beyond federal regulation, companies and providers face scrutiny and exposure from state medical and other professional boards, related to clinical practice standards such as telehealth standards of practice, licensure, informed consent, documentation, sourcing, and patient monitoring.
5. Investor interest is strong, but diligence must focus on regulatory durability. Investors should underwrite risk carefully – assessing regulatory exposure (including shifting FDA priorities and potential deregulation), litigation and IP risks, and the strength of compliance and sourcing practices. Investors should also evaluate margin sustainability and pressure-test exit scenarios, as ongoing regulatory uncertainty may impact buyer appetite and valuations.